A number of small molecules, such as histone deacetylase inhibitors12 and nicotinamide13, and large molecules, such as engineered transcription activator-like effectors14, 15, were reported as FXN upregulation approaches for FRDA therapy. The gene discussed is FXN; the disease is Friedreich ataxia.